Group 1 - Barclays PLC reduced its stake in Haotian International Construction Investment (01341) by 200.216 million shares at a price of HKD 0.0872 per share, totaling approximately HKD 17.4588 million [1] - After the reduction, Barclays PLC's remaining shareholding is approximately 573 million shares, representing a holding percentage of 5.16% [1]

Group 1 - Barclays PLC reduced its stake in Haotian International Construction Investment (01341) by 200.216 million shares at a price of HKD 0.0872 per share, totaling approximately HKD 17.4588 million [1] - After the reduction, Barclays' remaining shareholding is approximately 573 million shares, representing a holding percentage of 5.16% [1]

Core Viewpoint - Barclays PLC has reduced its stake in Haotian International Construction Investment (01341) by selling 200.216 million shares at a price of HKD 0.0872 per share, totaling approximately HKD 17.4588 million, resulting in a new holding of about 573 million shares, representing 5.16% ownership [1] Group 1 - Barclays PLC sold 200.216 million shares of Haotian International Construction Investment at HKD 0.0872 per share [1] - The total amount raised from the sale was approximately HKD 17.4588 million [1] - After the sale, Barclays PLC's remaining shares in Haotian International Construction Investment are approximately 573 million, equating to a 5.16% ownership stake [1]

Group 1 - Barclays PLC increased its stake in Longi Technology (02465) by 556,000 shares at a price of HKD 14.7961 per share, totaling approximately HKD 8.2266 million [1] - After the increase, Barclays' total shareholding in Longi Technology reached 7.5155 million shares, representing a holding percentage of 6.26% [1]

Group 1 - Barclays PLC increased its stake in Longpan Technology (02465) by acquiring 556,000 shares at a price of HKD 14.7961 per share, totaling approximately HKD 8.2266 million [1] - Following the acquisition, Barclays PLC's total shareholding in Longpan Technology reached 7.5155 million shares, representing a holding percentage of 6.26% [1]

Group 1 - Barclays PLC increased its stake in Longi Technology (02465) by 556,000 shares at a price of HKD 14.7961 per share, totaling approximately HKD 8.2266 million [1] - After the increase, Barclays' total shareholding in Longi Technology reached 7.5155 million shares, representing a holding percentage of 6.26% [1]

Group 1 - Barclays PLC increased its stake in Longpan Technology (02465.HK) by acquiring 1.711 million shares at an average price of HKD 15.3802 per share, totaling approximately HKD 26.3155 million [1] - Following this acquisition, Barclays PLC's total holdings in Longpan Technology rose to 6.9595 million shares, increasing its ownership percentage from 4.88% to 5.80% [1][2]

Core Viewpoint - Barclays PLC has increased its stake in Longi Technology (603906) (02465) by acquiring 1.711 million shares at a price of HKD 15.3802 per share, totaling approximately HKD 26.3155 million, raising its ownership to 6.9595 million shares, which represents 5.8% of the company [1]. Group 1 - Barclays PLC's recent acquisition of shares indicates a strategic move to enhance its investment in Longi Technology [1]. - The total amount spent on the share acquisition is approximately HKD 26.3155 million [1]. - Following the purchase, Barclays PLC's total shareholding in Longi Technology has increased to 6.9595 million shares [1].

Group 1 - Barclays PLC increased its stake in Longi Technology (02465) by acquiring 1.711 million shares at a price of HKD 15.3802 per share, totaling approximately HKD 26.3155 million [1] - Following the acquisition, Barclays PLC's total shareholding in Longi Technology reached 6.9595 million shares, representing a 5.8% ownership stake [1] - The increase in equity shares has resulted in a notifiable interest, with additional details regarding intragroup hedging between BBPLC and BCSL disclosed [1]

Group 1 - The core point of the article is that Barclays PLC has increased its stake in China National Pharmaceutical Group (China National Medicine) by purchasing 1.7788 million shares at an average price of HKD 77.7508 per share, totaling approximately HKD 138 million [1] - Following this transaction, Barclays PLC's total holdings in China National Medicine have risen to 6,467,742 shares, increasing its ownership percentage from 4.33% to 5.56% [1]